BCL3

B-cell lymphoma 3-encoded protein is a protein that in humans is encoded by the BCL3 gene.[5][6]

For BCl₃, see Boron trichloride.

BCL3
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1K1A, 1K1B
Identifiers
Aliases	BCL3, BCL4, D19S37, B-cell CLL/lymphoma 3, B cell CLL/lymphoma 3, transcription coactivator, BCL3 transcription coactivator
External IDs	OMIM: 109560 MGI: 88140 HomoloGene: 81738 GeneCards: BCL3
Gene location (Human) Chr. Chromosome 19 (human)[1] Band 19q13.32 Start 44,747,705 bp[1] End 44,760,044 bp[1]
Gene location (Mouse) Chr. Chromosome 7 (mouse)[2] Band 7 A3|7 9.95 cM Start 19,808,462 bp[2] End 19,822,770 bp[2]
RNA expression pattern More reference expression data
Gene ontology Molecular function • DNA binding • protein binding, bridging • GO:0001131, GO:0001151, GO:0001130, GO:0001204 DNA-binding transcription factor activity • transcription factor binding • GO:0001948 protein binding Cellular component • cytoplasm • Bcl3-Bcl10 complex • nucleoplasm • perinuclear region of cytoplasm • Bcl3/NF-kappaB2 complex • cell nucleus • cytosol • cell membrane • midbody • intracellular membrane-bounded organelle • macromolecular complex Biological process • regulation of apoptotic process • intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator • regulation of DNA binding • regulation of transcription, DNA-templated • T-helper 2 cell differentiation • antimicrobial humoral response • germinal center formation • response to virus • DNA damage response, signal transduction by p53 class mediator • extracellular matrix organization • positive regulation of interferon-gamma production • negative regulation of apoptotic process • spleen development • marginal zone B cell differentiation • positive regulation of translation • negative regulation of interleukin-8 biosynthetic process • transcription, DNA-templated • cellular response to DNA damage stimulus • positive regulation of transcription, DNA-templated • humoral immune response mediated by circulating immunoglobulin • follicular dendritic cell differentiation • negative regulation of tumor necrosis factor biosynthetic process • positive regulation of interleukin-10 biosynthetic process • defense response to bacterium • T-helper 1 type immune response • negative regulation of transcription, DNA-templated • I-kappaB kinase/NF-kappaB signaling • response to UV-C • maintenance of protein location in nucleus • positive regulation of transcription from RNA polymerase II promoter • defense response to protozoan • negative regulation of JAK-STAT cascade • regulation of NIK/NF-kappaB signaling Sources:Amigo / QuickGO
Orthologs
Species	Human	Mouse
Entrez	602	12051
Ensembl	ENSG00000069399	ENSMUSG00000053175
UniProt	P20749	Q9Z2F6
RefSeq (mRNA)	NM_005178	NM_033601
RefSeq (protein)	NP_005169	NP_291079
Location (UCSC)	Chr 19: 44.75 – 44.76 Mb	Chr 7: 19.81 – 19.82 Mb
PubMed search	[3]	[4]
Wikidata
View/Edit Human View/Edit Mouse

This gene is a proto-oncogene candidate. It is identified by its translocation into the immunoglobulin alpha-locus in some cases of B-cell leukemia. The protein encoded by this gene contains seven ankyrin repeats, which are most closely related to those found in I kappa B proteins. This protein functions as a transcriptional coactivator that activates through its association with NF-kappa B homodimers. The expression of this gene can be induced by NF-kappa B, which forms a part of the autoregulatory loop that controls the nuclear residence of p50 NF-kappa B.[7]

Like BCL2, BCL5, BCL6, BCL7A, BCL9, and BCL10, it has clinical significance in lymphoma.

Interactions

BCL3 has been shown to interact with:

• BARD1,[8]
• C-Fos,[9]
• C-jun,[9]
• C22orf25,[10]
• COPS5,[8]
• EP300,[9]
• HTATIP,[8]
• NFKB1,[11][12][13]
• NFKB2,[11][14]
• PIR,[8] and
• NR2B1.[15]

References

1. GRCh38: Ensembl release 89: ENSG00000069399 - Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000053175 - Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Wulczyn FG, Naumann M, Scheidereit C (Sep 1992). "Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B". Nature. 358 (6387): 597–9. doi:10.1038/358597a0. PMID 1501714.
6. Ohno H, Takimoto G, McKeithan TW (May 1990). "The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control". Cell. 60 (6): 991–7. doi:10.1016/0092-8674(90)90347-H. PMID 2180580.
7. "Entrez Gene: BCL3 B-cell CLL/lymphoma 3".
8. Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C, Leutz A (Jun 1999). "The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators". Oncogene. 18 (22): 3316–23. doi:10.1038/sj.onc.1202717. PMID 10362352.
9. Na SY, Choi JE, Kim HJ, Jhun BH, Lee YC, Lee JW (Oct 1999). "Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation". J. Biol. Chem. 274 (40): 28491–6. doi:10.1074/jbc.274.40.28491. PMID 10497212.
10. "Molecular Interaction Database". Archived from the original on 2006-05-06. Retrieved 2012-05-08.
11. Thornburg NJ, Pathmanathan R, Raab-Traub N (Dec 2003). "Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma". Cancer Res. 63 (23): 8293–301. PMID 14678988.
12. Naumann M, Wulczyn FG, Scheidereit C (January 1993). "The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B". EMBO J. 12 (1): 213–22. doi:10.1002/j.1460-2075.1993.tb05647.x. PMC 413194. PMID 8428580.
13. Heissmeyer V, Krappmann D, Wulczyn FG, Scheidereit C (Sep 1999). "NF-kappaB p105 is a target of IkappaB kinases and controls signal induction of Bcl-3-p50 complexes". EMBO J. 18 (17): 4766–78. doi:10.1093/emboj/18.17.4766. PMC 1171549. PMID 10469655.
14. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U (Mar 1993). "The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers". Cell. 72 (5): 729–39. doi:10.1016/0092-8674(93)90401-b. PMID 8453667.
15. Na SY, Choi HS, Kim JW, Na DS, Lee JW (Nov 1998). "Bcl3, an IkappaB protein, as a novel transcription coactivator of the retinoid X receptor". J. Biol. Chem. 273 (47): 30933–8. doi:10.1074/jbc.273.47.30933. PMID 9812988.

Further reading

• Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K, Siebenlist U (September 1992). "The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition". Nature. 359 (6393): 339–42. doi:10.1038/359339a0. PMID 1406939.
• Bhatia K, Huppi K, McKeithan T, Siwarski D, Mushinski JF, Magrath I (September 1991). "Mouse bcl-3: cDNA structure, mapping and stage-dependent expression in B lymphocytes". Oncogene. 6 (9): 1569–73. PMID 1923524.
• Mills FC, Brooker JS, Camerini-Otero RD (1991). "Sequences of human immunoglobulin switch regions: implications for recombination and transcription". Nucleic Acids Res. 18 (24): 7305–16. doi:10.1093/nar/18.24.7305. PMC 332867. PMID 2124350.
• Crossen PE, Kennedy MA, Heaton DC, Morrison MJ (1993). "Cloning and sequencing of a t(14;19) breakpoint that involves the C mu switch region". Genes Chromosomes Cancer. 8 (1): 60–2. doi:10.1002/gcc.2870080110. PMID 7691160.
• McKeithan TW, Ohno H, Dickstein J, Hume E (1995). "Genomic structure of the candidate proto-oncogene BCL3". Genomics. 24 (1): 120–6. doi:10.1006/geno.1994.1588. PMID 7896265.
• Zhang Q, Didonato JA, Karin M, McKeithan TW (1994). "BCL3 encodes a nuclear protein which can alter the subcellular location of NF-kappa B proteins". Mol. Cell. Biol. 14 (6): 3915–26. doi:10.1128/MCB.14.6.3915. PMC 358758. PMID 8196632.
• Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D (July 1993). "The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-kappa B p50 homodimers". Genes Dev. 7 (7B): 1354–63. doi:10.1101/gad.7.7b.1354. PMID 8330739.
• Naumann M, Wulczyn FG, Scheidereit C (1993). "The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B". EMBO J. 12 (1): 213–22. doi:10.1002/j.1460-2075.1993.tb05647.x. PMC 413194. PMID 8428580.
• Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U (March 1993). "The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers". Cell. 72 (5): 729–39. doi:10.1016/0092-8674(93)90401-B. PMID 8453667.
• Nolan GP, Fujita T, Bhatia K, Huppi C, Liou HC, Scott ML, Baltimore D (June 1993). "The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner". Mol. Cell. Biol. 13 (6): 3557–66. doi:10.1128/MCB.13.6.3557. PMC 359825. PMID 8497270.
• Watanabe N, Iwamura T, Shinoda T, Fujita T (June 1997). "Regulation of NFKB1 proteins by the candidate oncoprotein BCL-3: generation of NF-kappaB homodimers from the cytoplasmic pool of p50-p105 and nuclear translocation". EMBO J. 16 (12): 3609–20. doi:10.1093/emboj/16.12.3609. PMC 1169985. PMID 9218802.
• Bundy DL, McKeithan TW (1998). "Diverse effects of BCL3 phosphorylation on its modulation of NF-kappaB p52 homodimer binding to DNA". J. Biol. Chem. 272 (52): 33132–9. doi:10.1074/jbc.272.52.33132. PMID 9407099.
• Weyrich AS, Dixon DA, Pabla R, Elstad MR, McIntyre TM, Prescott SM, Zimmerman GA (May 1998). "Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets". Proc. Natl. Acad. Sci. U.S.A. 95 (10): 5556–61. doi:10.1073/pnas.95.10.5556. PMC 20416. PMID 9576921.
• Na SY, Choi HS, Kim JW, Na DS, Lee JW (November 1998). "Bcl3, an IkappaB protein, as a novel transcription coactivator of the retinoid X receptor". J. Biol. Chem. 273 (47): 30933–8. doi:10.1074/jbc.273.47.30933. PMID 9812988.
• Dechend R, Hirano F, Lehmann K, Heissmeyer V, Ansieau S, Wulczyn FG, Scheidereit C, Leutz A (June 1999). "The Bcl-3 oncoprotein acts as a bridging factor between NF-kappaB/Rel and nuclear co-regulators". Oncogene. 18 (22): 3316–23. doi:10.1038/sj.onc.1202717. PMID 10362352.
• Na SY, Choi JE, Kim HJ, Jhun BH, Lee YC, Lee JW (October 1999). "Bcl3, an IkappaB protein, stimulates activating protein-1 transactivation and cellular proliferation". J. Biol. Chem. 274 (40): 28491–6. doi:10.1074/jbc.274.40.28491. PMID 10497212.
• Neumann M, Fries H, Scheicher C, Keikavoussi P, Kolb-Mäurer A, Bröcker E, Serfling E, Kämpgen E (January 2000). "Differential expression of Rel/NF-kappaB and octamer factors is a hallmark of the generation and maturation of dendritic cells". Blood. 95 (1): 277–85. PMID 10607713.
• Brasier AR, Lu M, Hai T, Lu Y, Boldogh I (August 2001). "NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence". J. Biol. Chem. 276 (34): 32080–93. doi:10.1074/jbc.M102949200. PMID 11387332.

External links

• FactorBook BCL3
• Human BCL3 genome location and BCL3 gene details page in the UCSC Genome Browser.